• Enzymatica AB is a Swedish life science company that develops and sells medical devices with barrier technology for infection-related diseases.

Sustainability

Enzymatica wants to be a good stakeholder in the community and take responsibility for sustainable social development.

As a medical device company, Enzymatica focuses on human health and well-being, and wants to use resources, regardless of whether they are raw materials, energy or human, as wisely and sustainably as possible.

Regarding basic research, production and sales of products, the Company cooperates to a large extent with partners, many of whom actively work with sustainability issues.

ColdZyme® against common cold

ColdZyme reduces the risk of catching a cold and shortens the duration of illness at an early stage of infection.

  • Product development

    Enzymatica focuses on product development based on the tested and patented barrier technology used in the cold product ColdZyme. Strengthening the clinical documentation for ColdZyme is a key part of Enzymatica’s R&D activities.

Investors

Extensive market and strong presence on the home market

Enzymatica operates on a large market, colds, with strong underlying growth.  The market for over-the-counter cold products amounted to USD 21 billion in 2017.  Enzymatica has established a strong position on the home market in Sweden with a market share for ColdZyme of 5.6%, based on rolling 12-month data at year-end 2018/2019.

We are also building a strong distributor network – in 2018 we signed distributor agreements for South Africa, Hong Kong & Macau, and Japan.

Contact us

Enzymatica AB
Ideon Science Park
SE-223 70 Lund, Sweden
Telefon: +46 46-286 31 00
E-mail: info@enzymatica.se